Remit - To appraise the clinical and cost effectiveness of crizanlizumab within its marketing authorisation for preventing sickle cell crises in sickle cell disease
 
Status In progress
Process STA 2018
ID number 1406

Provisional Schedule

Expected publication 27 January 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Novartis (crizanlizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Sickle Cell and Young Stroke Survivors (SCYSS)
  Sickle Cell Society
Professional groups Royal College of Paediatrics and Child Health
  Royal College of Physicians

Commentators

Comparator companies Bristol-Myers Squibb (hydroxycarbamide)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
26 November 2020 - 17 December 2020 Appraisal consultation
04 November 2020 Committee meeting: 1
06 April 2020 In progress. Topic is in progress
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
03 December 2019 Following a regulatory update from the company, Novartis Pharmaceuticals, the timings for this appraisal have been amended, The first committee meeting has been rescheduled to 4 November 2020.
25 October 2019 Invitation to participate
22 March 2019 - 19 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance